在神经退行性疾病中,病原蛋白聚合物的自我传播
Mathias Jucker1, Lary C Walker
1Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, D-72076 Tübingen, Germany. mathias.jucker@uni-tuebingen.de
Nature
|September 6, 2013
概括
病研究为与年龄相关的神经退行性疾病提供了洞察力. 了解蛋白质的错误折叠和聚合,类似于子,可能会为阿尔茨海默氏症等疾病提供新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 与年龄相关的神经退行性疾病是一个重大的健康问题.
- 长期以来,人们一直猜测,以蛋白质错折为特征的子疾病是理解这些条件的关键.
- 最近疾病模型的进步为这一假设提供了实验支持.
研究的目的:
- 探索类蛋白质误折叠和聚合在神经退行症中的作用.
- 为一系列神经疾病建立一个统一的致病原理.
- 识别基于子范式的潜在治疗策略.
主要方法:
- 审查最近的实验发现和疾病模型.
- 分析蛋白质错误折叠和聚合机制.
- 在病和其他蛋白病变中对病原性途径进行比较.
主要成果:
- 特定的蛋白质错误地折叠和聚合成自我繁殖的种子.
- 这些种子破坏其他蛋白质,导致致病性组合 (从寡合体到粉样蛋白).
- 蛋白质腐败的新生和传染性起源都会导致神经系统的损害.
结论:
- 子范式为了解各种神经退行性疾病提供了一个统一的原则.
- 含蛋白质的种子作为驱动疾病诱发和进展的代理物.
- 这种理解表明,对于像阿尔茨海默氏症这样的难以治疗的神经疾病,广泛适用的治疗方向.
相关概念视频
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Encephalitis ll: Pathophysiology
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...


